$1.53 Million in Sales Expected for Uniqure NV (QURE) This Quarter
Wall Street analysts expect Uniqure NV (NASDAQ:QURE) to post sales of $1.53 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Uniqure’s earnings, with the lowest sales estimate coming in at $1.00 million and the highest estimate coming in at $2.50 million. Uniqure reported sales of $3.05 million during the same quarter last year, which indicates a negative year over year growth rate of 49.8%. The firm is scheduled to announce its next earnings results on Wednesday, August 14th.
On average, analysts expect that Uniqure will report full year sales of $6.66 million for the current year, with estimates ranging from $4.14 million to $10.85 million. For the next fiscal year, analysts anticipate that the firm will report sales of $9.54 million, with estimates ranging from $4.00 million to $25.40 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Uniqure.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%.
NASDAQ:QURE traded up $2.41 during trading hours on Thursday, reaching $63.49. 484,819 shares of the company were exchanged, compared to its average volume of 485,202. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.38. The company has a market cap of $2.33 billion, a P/E ratio of -27.13 and a beta of 0.99. Uniqure has a 52-week low of $21.98 and a 52-week high of $69.60.
In related news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $58.38, for a total transaction of $467,040.00. Following the completion of the sale, the chief executive officer now directly owns 421,730 shares of the company’s stock, valued at approximately $24,620,597.40. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $57.18, for a total transaction of $88,400.28. Following the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. In the last three months, insiders sold 82,922 shares of company stock worth $5,223,849. Insiders own 1.56% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harvest Group Wealth Management LLC acquired a new stake in Uniqure during the 1st quarter valued at $26,000. Legal & General Group Plc grew its holdings in Uniqure by 264.2% during the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 700 shares in the last quarter. Kore Private Wealth LLC acquired a new position in Uniqure during the 1st quarter worth $30,000. Pearl River Capital LLC acquired a new position in Uniqure during the 1st quarter worth $32,000. Finally, SEI Investments Co acquired a new position in Uniqure during the 1st quarter worth $35,000. 61.30% of the stock is owned by institutional investors and hedge funds.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Recommended Story: Market Capitalization – What it Means for Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.